| Recruiting | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenoc NCT06846346 | UNICANCER | Phase 2 |
| Recruiting | Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With P NCT06675136 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Ch NCT07043400 | BeOne Medicines | Phase 3 |
| Recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Recruiting | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatm NCT06324357 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Recruiting | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastri NCT05927857 | National Health Research Institutes, Taiwan | Phase 1 / Phase 2 |
| Recruiting | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People Wit NCT06251973 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastati NCT05677490 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors NCT05555251 | BioInvent International AB | Phase 1 / Phase 2 |
| Unknown | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Ca NCT05342389 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno NCT05041153 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Recruiting | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv NCT04660760 | Academic and Community Cancer Research United | Phase 2 |
| Unknown | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cance NCT04781686 | Zhou Fuxiang | Phase 2 |
| Active Not Recruiting | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gast NCT03641313 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Ga NCT04248452 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer NCT04220827 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Ga NCT03918499 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Unknown | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With NCT03990103 | China Medical University, China | Phase 2 |
| Unknown | Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA NCT03116555 | China Medical University, China | Phase 2 |
| Completed | A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma NCT02539225 | Eli Lilly and Company | Phase 2 |
| Unknown | A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma NCT03071042 | Sir Run Run Shaw Hospital | Phase 1 |
| Completed | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach NCT02314117 | Eli Lilly and Company | Phase 3 |
| Terminated | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Rec NCT02391038 | Millennium Pharmaceuticals, Inc. | Phase 1 |